# Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma

> **NCT05703854** · PHASE1,PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 50 (estimated)

## Conditions studied

- Advanced Renal Cell Carcinoma
- Advanced Mesothelioma
- Advanced Osteosarcoma

## Interventions

- **DRUG:** CAR.70/IL15-transduced CB-derived NK cells
- **DRUG:** Fludarabine phosphate
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT05703854
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-29
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05703854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05703854, "Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05703854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*